Home › Islet Cell Adenoma › Illinois › Chicago
Islet Cell Adenoma clinical trials in Chicago, IL
4 studies for Islet Cell Adenoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
- Investigative Site, Chicago
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
RecruitingPhase 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
RecruitingPhase 2
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Islet Cell Adenoma trials in other cities
- Los Angeles, CA6 studies
- Rochester, MN5 studies
- Washington, DC4 studies
- Phoenix, AZ4 studies
- Portland, OR4 studies
- St. Louis, MO4 studies
- Nashville, TN3 studies
- Boston, MA3 studies
- Lexington, KY3 studies
- Columbus, OH3 studies
- Philadelphia, PA3 studies
- Salt Lake City, UT3 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.